Friday, 20 April 2018

Prime Therapeutics Finds Costs Double When Switching to New Extended Half-Life Hemophilia Factor Products

  1. Prime Therapeutics Finds Costs Double When Switching to New Extended Half-Life Hemophilia Factor Products  Markets InsiderFull coverage

No comments:

Post a Comment